Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator and exporter,
announces it will present performance results of its Quality
Assessment Products (“
QAPs™”) supporting Human
Papillomavirus (“
HPV”) molecular-diagnostic
screening-tests at the 2022 annual congress of the European
Research Organization on Genital Infection and Neoplasia
(“
EUROGIN”) taking place in Düsseldorf, Germany
from April 10-12, 2022.
At EUROGIN, Microbix will be exhibiting
alongside leading diagnostics firms that provide screening-tests
for detection of HPV infections. Microbix has QAPs to support tests
for eight (8) high-risk HPV types available for sale in Canada,
Europe, the United States, and other commercially-important
jurisdictions under its “REDx™ Controls” or
“PROCEEDx™” brand names. Most sexually-active
adults become infected with one or more types of HPV and its
high-risk types are well-known and common causes of human cancers.
Tests to detect infection with high-risk HPV provide important
preventative health information and require validated, regulated,
and third-party test-controls to help ensure their accuracy.
Microbix will also review performance of its
multiplex high-risk HPV QAPs in supporting quality management of
testing for high-risk types of HPV via full and extended genotyping
assays. Its poster presentation is titled “Performance of full and
extended genotyping assays using a new high-risk HPV multiplex
panel.” The poster details the performance of multiplex high-risk
HPV QAPs in supporting BD Onclarity™ assays and Microbix gratefully
acknowledges the assistance of Becton Dickinson Life Sciences in
planning and executing these evaluations. The poster will be
available on Microbix’s website (https://microbix.com) and from
EUROGIN following its presentation.
Furthermore, Microbix is proud to announce
collaboration with Copan Italia S.p.A. (“Copan®”)
and key opinion leaders at VCS Pathology (Victoria, Australia) to
advance self-collection HPV molecular diagnostic
(“MDx”) testing. A presentation titled “Validation
of MSwab™ medium for the elution of FLOQSwabs® for human
papillomavirus (HPV) detection on six commercial PCR-based HPV
assays” will demonstrate new self-sampling tools for HPV screening
programs. Empowering patients to collect samples in private and
convenient locations is expected to speed widespread adoption of
MDx-driven HPV screening programs. Microbix is proud to be a
strategic partner of Copan and offer HPV-oriented
“PROCEED™FLOQ®” (RUO) and prospective
“REDx™FLOQ®” (IVD) QAPs to support self-collection
screening programs worldwide. Purchase enquiries for Microbix’s
QAPs™ can be e-mailed to customer.service@microbix.com.
Prior to the pandemic, healthcare systems were
preparing MDX-based HPV screening programs to identify individuals
at risk years before cancerous cells can be detected using
pathology. Such programs were delayed due to MDx capacity being
coopted for COVID-testing, but are now being reconsidered as COVID
becomes endemic. Microbix believes many high-risk HPV infections
and resulting cancers have gone undiagnosed and is pleased to help
enable the resumption and expansion of MDx screening programs.
About Microbix
BiosystemsMicrobix develops proprietary biological
technology solutions for human health and well-being, with over 100
skilled employees and sales approaching C$ 2.0 million per month.
It makes a wide range of critical biological materials for the
global diagnostics industry, notably antigens for immunoassays and
its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Microbix antigens enable the antibody tests of over 100
international diagnostics companies, while its QAPs are sold to
clinical laboratory accreditation organizations, diagnostics
companies, and clinical laboratories. Microbix QAPs are now
available in over 30 countries, distributed by 1WA (Oneworld
Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International
Distribution SpA., Labquality Oy, The Medical Supply Company of
Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc.,
and Thomas Scientific LLC. Microbix is ISO 9001 and 13485
accredited, U.S. FDA registered, Australian TGA registered, Health
Canada establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of EUROGIN,
the poster or its relevance, the products of Microbix or its
collaborators, Microbix’s business and business results, goals or
outlook, risks associated with financial results and stability,
development projects such as those referenced in its corporate
presentation, regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity and timeliness of delivery),
foreign currency and exchange rates, maintaining adequate working
capital or raising further capital on acceptable terms or at all,
and other similar statements concerning anticipated future events,
conditions or results that are not historical facts. These
statements reflect management’s current estimates, beliefs,
intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking
information is inherently uncertain and that actual performance may
be affected by a number of material factors, many of which are
beyond the Company’s control. Accordingly, actual future events,
conditions and results may differ materially from the estimates,
beliefs, intentions and expectations expressed or implied in the
forward-looking information. All statements are made as of the date
of this news release and represent the Company’s judgement as of
the date of this new release, and the Company is under no
obligation to update or alter any forward-looking information.
Please visit https://microbix.com or www.sedar.com
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome,CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Jim Macdonald,Investor RelationsTorrey Hills Capital(858)
456-7300jm@sdthc.com |
Copyright © 2022 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, PROCEEDx™, QAPs™, REDx™ and REDx™
Controls are trademarks of Microbix Biosystems Inc.PROCEEDx™FLOQ®
and REDx™FLOQ® are trademarks of Microbix Biosystems Inc. in
collaboration with Copan Italia S.p.A.BD Onclarity™ is a trademark
of Becton Dickinson and Company or an affiliate.Copan®, FLOQ®, and
FLOQSwab® are trademarks of Copan Italia S.p.A.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Oct 2023 to Oct 2024